Remidio, received CDSCO approval for its Medios DR AI, which is used with its portable retinal cameras. This approval comes after the same solution received CE marking under EU-MDR guidelines and HSA ...

Tinlarebant is an oral therapy designed to reduce the accumulation of vitamin A based toxins that cause retinal disease.

According to the company, the axitinib injectable suspension achieved all primary and secondary outcomes and maintained stable visual acuity and anatomical control over 9 months. There were no ocular ...

Everads suprachoroidal delivery technology is designed to enable safe and effective in-office delivery of therapies to the choroidal and retinal tissues via the suprachoroidal space. Everads Therapy ...